Phase I/Ib Study of Olaparib and Carboplatin in BRCA1 or BRCA2 Mutation-Associated Breast or Ovarian Cancer With Biomarker Analyses
Jung Min Lee(Kyung Hee University), Elise C. Kohn(National Cancer Institute), Anne M. Noonan(The Ohio State University), Jiuping Ji(Pancreatic Cancer Action Network), Bradford J. Wood(National Institutes of Health), Christina M. Annunziata(National Cancer Institute), Lori M. Minasian(National Cancer Institute), James H. Doroshow(National Cancer Institute), Tristan M. Sissung(National Institutes of Health), Nicolas Gordon(National Institutes of Health), Nilofer S. Azad(Johns Hopkins Hospital), William D. Figg(National Cancer Institute), John L. Hays(The Ohio State University), Minshu Yu(National Institutes of Health), Jo Anne Zujewski
Cited by 184
Related Papers
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
|New England Journal of Medicine|2015|9.4k
Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
|Science Translational Medicine|2014|5.1k
Development of the National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)
|JNCI Journal of the National Cancer Institute|2014|1.1k